tbuckley/cabot-search huggingface dataset:
Artificial intelligence for polyp detection during colonoscopy: a systematic review and meta-analysis
Authors: Ishita Barua, Daniela Guerrero Vinsard, Henriette C. Jodal, Magnus Løberg, Mette Kalager, Øyvind Holme, Masashi Misawa, Michael Bretthauer, Yuichi Mori
Journal: Endoscopy (2020)

Abstract Background Artificial intelligence (AI)-based polyp detection systems are used during colonoscopy with the aim of increasing lesion detection and improving colonoscopy quality. Patients and methods: We performed a systematic review and meta-analysis of prospective trials to determine the value of AI-based polyp detection systems for detection of polyps and colorectal cancer. We performed systematic searches in MEDLINE, EMBASE, and Cochrane CENTRAL. Independent reviewers screened studies and assessed eligibility, certainty of evidence, and risk of bias. We compared colonoscopy with and without AI by calculating relative and absolute risks and mean differences for detection of polyps, adenomas, and colorectal cancer. Results Five randomized trials were eligible for analysis. Colonoscopy with AI increased adenoma detection rates (ADRs) and polyp detection rates (PDRs) compared to colonoscopy without AI (values given with 95 %CI). ADR with AI was 29.6 % (22.2 % – 37.0 %) versus 19.3 % (12.7 % – 25.9 %) without AI; relative risk (RR] 1.52 (1.31 – 1.77), with high certainty. PDR was 45.4 % (41.1 % – 49.8 %) with AI versus 30.6 % (26.5 % – 34.6 %) without AI; RR 1.48 (1.37 – 1.60), with high certainty. There was no difference in detection of advanced adenomas (mean advanced adenomas per colonoscopy 0.03 for each group, high certainty). Mean adenomas detected per colonoscopy was higher for small adenomas (≤ 5 mm) for AI versus non-AI (mean difference 0.15 [0.12 – 0.18]), but not for larger adenomas (&gt; 5 – ≤ 10 mm, mean difference 0.03 [0.01 – 0.05]; &gt; 10 mm, mean difference 0.01 [0.00 – 0.02]; high certainty). Data on cancer are unavailable. Conclusions AI-based polyp detection systems during colonoscopy increase detection of small nonadvanced adenomas and polyps, but not of advanced adenomas.
Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer
Authors: Ben O’Leary, Rosalind J Cutts, Xin Huang, Sarah Hrebien, Yuan Liu, Fabrice André, Sibylle Loibl, Sherene Loi, Isaac Garcia-Murillas, Massimo Cristofanilli, Cynthia Huang Bartlett, Nicholas C Turner
Journal: JNCI Journal of the National Cancer Institute (2020)

Abstract Background There are no established molecular biomarkers for patients with breast cancer receiving combination endocrine and CDK4/6 inhibitor (CDK4/6i). We aimed to determine whether genomic markers in circulating tumor DNA (ctDNA) can identify patients at higher risk of early progression on fulvestrant therapy with or without palbociclib, a CDK4/6i. Methods PALOMA-3 was a phase III, multicenter, double-blind randomized controlled trial of palbociclib plus fulvestrant (n = 347) vs placebo plus fulvestrant (n = 174) in patients with endocrine-pretreated estrogen receptor–positive (ER+) breast cancer. Pretreatment plasma samples from 459 patients were analyzed for mutations in 17 genes, copy number in 14 genes, and circulating tumor fraction. Progression-free survival (PFS) was compared in patients with circulating tumor fraction above or below a prespecified cutoff of 10% and with or without a specific genomic alteration. All statistical tests were 2-sided. Results Patients with high ctDNA fraction had worse PFS on both palbociclib plus fulvestrant (hazard ratio [HR] = 1.62, 95% confidence interval [CI] = 1.17 to 2.24; P = .004) and placebo plus fulvestrant (HR = 1.77, 95% CI = 1.21 to 2.59; P = .004). In multivariable analysis, high-circulating tumor fraction was associated with worse PFS (HR = 1.20 per 10% increase in tumor fraction, 95% CI = 1.09 to 1.32; P &amp;lt; .001), as was TP53 mutation (HR = 1.84, 95% CI = 1.27 to 2.65; P = .001) and FGFR1 amplification (HR = 2.91, 95% CI = 1.61 to 5.25; P &amp;lt; .001). No interaction with treatment randomization was observed. Conclusions Pretreatment ctDNA identified a group of high-risk patients with poor clinical outcome despite the addition of CDK4/6 inhibition. These patients might benefit from inclusion in future trials of escalating treatment, with therapies that may be active in these genomic contexts.
Abstract B55: PIK3CA mutation enrichment and detection in clinical samples
Authors: Ieva Keraite, Virginia Alvarez-Garcia, Jurgen Del Favero, Maiwenn Kersaudy-Kerhoas, Nicholas Leslie
Journal: Clinical Cancer Research (2020)

Abstract The PI3K/AKT/mTOR signaling pathway is one of the most frequently mutated pathways in human cancers, including breast cancer. Given the current urge for more personalized approaches, there is an increasing need for a rigorous list of biomarkers and detection methods with advanced, less-invasive, reliable, and low-cost technologies. Despite limited clinical results to date, the detection of PIK3CA mutations shows great potential to contribute in cancer patient management in the future at many different levels, including diagnosis, treatment choice and monitoring, and identification of drug resistance. However, current molecular methods still lack analytical sensitivity to detect mutations of low abundance in high wild-type DNA background. Makrigiorgos et al. recently developed a nuclease-assisted minor-allele enrichment assay with overlapping probes, which is practical and cost-effective and allows detection of very-low-abundance mutations that could have relevance in the clinic. Thus we aimed to develop PIK3CA mutation-specific nuclease-based enrichment assay and validate it with tissue biopsy and blood samples using crystal dPCR as well as combine it with our developed Sybr Green real-time qPCR detection method (Alvarez-Garcia et al. 2018), which allows a quick detection of PIK3CA mutations in clinical samples at low cost. Citation Format: Ieva Keraite, Virginia Alvarez-Garcia, Jurgen Del Favero, Maiwenn Kersaudy-Kerhoas, Nicholas Leslie. PIK3CA mutation enrichment and detection in clinical samples [abstract]. In: Proceedings of the AACR Special Conference on Advances in Liquid Biopsies; Jan 13-16, 2020; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(11_Suppl):Abstract nr B55.
Reticular Fibroblasts Expressing the Transcription Factor WT1 Define a Stromal Niche that Maintains and Replenishes Splenic Red Pulp Macrophages
Authors: Alicia Bellomo, Isabelle Mondor, Lionel Spinelli, Marine Lagueyrie, Benjamin J. Stewart, Nicolas Brouilly, Bernard Malissen, Menna R. Clatworthy, Marc Bajénoff
Journal: Immunity (2020)
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial
Authors: Tali Cukierman-Yaffe, Hertzel C Gerstein, Helen M Colhoun, Rafael Diaz, Luis-Emilio García-Pérez, Mark Lakshmanan, Angelyn Bethel, Denis Xavier, Jeffrey Probstfield, Matthew C Riddle, Lars Rydén, Charles Messan Atisso, Stephanie Hall, Purnima Rao-Melacini, Jan Basile, William C Cushman, Edward Franek, Matyas Keltai, Fernando Lanas, Lawrence A Leiter, Patricio Lopez-Jaramillo, Valdis Pirags, Nana Pogosova, Peter J Raubenheimer, Jonathan E Shaw, Wayne H-H Sheu, Theodora Temelkova-Kurktschiev
Journal: The Lancet Neurology (2020)
Nonosmolar Factors Affecting Renal Water Excretion
Authors: Robert W. Schrier, Tomas Berl
Journal: New England Journal of Medicine (1975)

Physical and Emotional StressDuring their careful studies in conscious dogs, Verney and Rydin4 observed that exercise, as well as a sudden noxious stimulus capable of frightening the animal, was followed by a decrease in urine flow. Since then, the association of both physical31 and emotional103 stress with impaired water excretion has been well recognized. The original observations of Verney shed some light on the mechanism involved in this antidiuresis.104 He suggested that the associated changes in renal blood flow were not likely to account for the change in urine flow, and demonstrated that the antidiuresis . . .
Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)
Authors: Andreas Neubauer, Thomas Wiesmann, Claus F. Vogelmeier, Elisabeth Mack, Chrysanthi Skevaki, Christine Gaik, Christian Keller, Jens Figiel, Kristina Sohlbach, Caroline Rolfes, Harald Renz, Hinnerk Wulf, Andreas Burchert
Journal: Leukemia (2020)

Since its outbreak in December 2019 in Wuhan, China [1], the novel coronavirus, SARS-CoV-2, has created a dramatic global health and economic crisis.COVID-19 is the disease caused by SARS-CoV-2.In most cases, COVID-19 is associated with mild respiratory symptoms.However, in ~15% of the patients, hospitalization is required, and about 5% of patients develop severe lung injury that can result in acute respiratory distress syndrome (ARDS).ARDS may be accompanied by sepsis and septic shock, and multiorgan failure, including acute kidney injury and cardiac injury.Older age, obesity, pulmonary and other comorbidities are risk factors for higher mortality [2,3].It has also been reported that the extent of inflammation-mirrored by peripheral blood cytokine levels-is associated with a worse outcome [4].LaRosée et al. describe a very interesting series of 14 COVID-19 patients with heavy inflammatory syndrome treated successfully with ruxolitinib [5].As COVID-19 induces significant burden to societies worldwide, appropriate treatment also for COVID-19 associated ARDS would be beneficial.However, in the 14 patients described in this series, only one patient was mechanically ventilated before start of ruxolitinib.
α<sub>1</sub>-antitrypsin PI*SZ genotype: a SERPINA1 deficiency haplotype with uncertain clinical and therapeutic implications
Authors: Ignacio Blanco, Isidro Diego
Journal: European Respiratory Journal (2020)

<b>Despite its high prevalence and being one of the first genotypes identified in the field of α<sub>1</sub>-antitrypsin deficiency, the PI*SZ genotype has been little studied, and many unknowns regarding its clinical significance remain unanswered.</b>https://bit.ly/3aut4ZE
Missed Opportunities on Emergency Remdesivir Use
Authors: Ameet Sarpatwari, Anna Kaltenboeck, Aaron S. Kesselheim
Journal: JAMA (2020)

Christoph D. Spinner, MD; Robert L. Gottlieb, MD, PhD; Gerard J. Criner, MD; José Ramón Arribas López, MD; Anna Maria Cattelan, MD; Alex Soriano Viladomiu, MD; Onyema Ogbuagu, MD; Prashant Malhotra, MD; Kathleen M. Mullane, DO; Antonella Castagna, MD; Louis Yi Ann Chai, MD; Meta Roestenberg, MD; Owen Tak Yin Tsang, MD; Enos Bernasconi, MD; Paul Le Turnier, MD; Shan-Chwen Chang, MD; Devi SenGupta, MD; Robert H. Hyland, DPhil; Anu O. Osinusi, MD; Huyen Cao, MD; Christiana Blair, MS; Hongyuan Wang, PhD; Anuj Gaggar, MD, PhD; Diana M. Brainard, MD; Mark J. McPhail, MD; Sanjay Bhagani, MD; Mi Young Ahn, MD; Arun J. Sanyal, MD; Gregory Huhn, MD; Francisco M. Marty, MD; for the GS-US-540-5774 Investigators
Treatment of toenail tinea infection
Authors: D. S Buck
Journal: BMJ (1996)

or radio (162) and newspapers (1 19) we believe that these are important vehicles for increasing public awareness of this disease.In the light of our findings we suggest that future publicity should emphasise that meningitis is not a threat only to babies and young children and that teenagers and elderly people are also particularly at risk.The importance of a petechial or purpuric rash that does not fade when pressure is applied and the need for immediate action when such a rash is found should also be highlighted.
The high cost of prescription drugs: causes and solutions
Authors: S. Vincent Rajkumar
Journal: Blood Cancer Journal (2020)

Global spending on prescription drugs in 2020 is expected to be ~$1.3trillion; the United States alone will spend ~$350 billion 1 .These high spending rates are expected to increase at a rate of 3-6% annually worldwide.The magnitude of increase is even more alarming for cancer treatments that account for a large proportion of prescription drug costs.In 2018, global spending on cancer treatments was approximately 150 billion, and has increased by >10% in each of the past 5 years 2 .The high cost of prescription drugs threatens healthcare budgets, and limits funding available for other areas in which public investment is needed.In countries without universal healthcare, the high cost of prescription drugs poses an additional threat: unaffordable out-of-pocket costs for individual patients.Approximately 25% of Americans find it difficult to afford prescription drugs due to high out-ofpocket costs 3 .Drug companies cite high drug prices as being important for sustaining innovation.But the ability to charge high prices for every new drug possibly slows the pace of innovation.It is less risky to develop drugs that represent minor modifications of existing drugs ("me-too" drugs) and show incremental improvement in efficacy or safety, rather than investing in truly innovative drugs where there is a greater chance of failure.
Prehabilitation vs Postoperative Rehabilitation for Frail Patients
Authors: Bart C. Bongers, Joost M. Klaase, Nico L. U. van Meeteren
Journal: JAMA Surgery (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts
Authors: Amer M Zeidan, Prajwal C Boddu, Mrinal M Patnaik, Jan Philipp Bewersdorf, Maximilian Stahl, Raajit K Rampal, Rory Shallis, David P Steensma, Michael R Savona, Mikkael A Sekeres, Gail J Roboz, Daniel J DeAngelo, Andre C Schuh, Eric Padron, Joshua F Zeidner, Roland B Walter, Francesco Onida, Amir Fathi, Amy DeZern, Gabriela Hobbs, Eytan M Stein, Paresh Vyas, Andrew H Wei, David T Bowen, Pau Montesinos, Elizabeth A Griffiths, Amit K Verma, Alla Keyzner, Michal Bar-Natan, Shyamala C Navada, Marina Kremyanskaya, Aaron D Goldberg, Aref Al-Kali, Mark L Heaney, Aziz Nazha, Huda Salman, Selina Luger, Keith W Pratz, Heiko Konig, Rami Komrokji, Michael Deininger, Blanca Xicoy Cirici, Vijaya Raj Bhatt, Lewis R Silverman, Harry P Erba, Pierre Fenaux, Uwe Platzbecker, Valeria Santini, Eunice S Wang, Martin S Tallman, Richard M Stone, John Mascarenhas
Journal: The Lancet Haematology (2020)
Functional characteristics of patients with SARS-CoV-2 pneumonia at 30 days post-infection
Authors: Justine Frija-Masson, Marie-Pierre Debray, Marie Gilbert, François-Xavier Lescure, Florence Travert, Raphaël Borie, Antoine Khalil, Bruno Crestani, Marie-Pia d'Ortho, Catherine Bancal
Journal: European Respiratory Journal (2020)

<b>More than half of patients with COVID-19 pneumonia exhibit abnormal lung function 30 days after symptom onset, without clear relationship with pneumonia extent on chest CT. This pleads for systematic and long-term follow-up of patients with COVID-19.</b>https://bit.ly/2TFMPqE
Left Atrial Late Gadolinium Enhancement is Associated With Incident Atrial Fibrillation as Detected by Continuous Monitoring With Implantable Loop Recorders
Authors: Litten Bertelsen, Søren Zöga Diederichsen, Ketil Jørgen Haugan, Axel Brandes, Claus Graff, Derk Krieger, Christian Kronborg, Lars Køber, Dana C. Peters, Morten Salling Olesen, Søren Højberg, Niels Vejlstrup, Jesper Hastrup Svendsen
Journal: JACC. Cardiovascular imaging (2020)
Assessment of Hazard Ratios in Oncology Clinical Trials Terminated Early for Superiority
Authors: Masashi Shimura, Shogo Nomura, Masashi Wakabayashi, Kazushi Maruo, Masahiko Gosho
Journal: JAMA Network Open (2020)

<h3>Importance</h3> Group sequential designs allow potential early trial termination at the interim analysis, before study completion. Traditional maximum likelihood estimate is commonly used to quantify the treatment effect in group sequential design trials; however, in published clinical trials, a bias-adjusted estimator has rarely been reported. <h3>Objective</h3> To emphasize the need for considering overestimation of treatment effect by applying 2 bias-adjusted estimators to previously published, early-terminated oncology clinical trials. <h3>Evidence Review</h3> Trials published from 2013 to 2017 were identified by searching MEDLINE and Embase on February 23, 2018. This review was restricted to oncology clinical trials using group sequential designs with a single preplanned interim analysis as well as 2-arm randomized clinical trials that were subsequently stopped for efficacy reasons. Each article was independently reviewed by 3 biostatisticians during text screening, and differences in opinion were resolved by discussion. This report presents the unadjusted hazard ratio (HR) of an experimental arm to a reference arm and 2 bias-adjusted HRs calculated by using the conditional mean-adjusted estimator (CMAE) and weighted CMAE (WCMAE). <h3>Findings</h3> In total, 198 abstracts were screened for eligibility, of which, 19 eligible clinical trials were identified as applicable to the bias-adjusted estimators. Unadjusted HRs ranged from 0.203 (95% CI, 0.150-0.276) to 0.71 (95% CI, 0.60-0.84), number of events at the interim analysis from 58 to 540, and information time from 48% to 82%. In each study, the HRs adjusted by CMAE and WCMAE were higher than the unadjusted HR. Bias-adjusted estimates in large trials (243 and 414 events at the interim analysis) were similar to the unadjusted HR. However, in small trials (eg, with 58 events at the interim analysis), bias-adjusted estimates were highly disparate from the unadjusted HR. In trials with large treatment effects (eg, HRs of 0.20 and 0.22), the difference between unadjusted and bias-adjusted HRs was small even though the number of events at the interim analysis was small; larger differences were observed when the unadjusted HR was greater than 0.5. <h3>Conclusions and Relevance</h3> In this systematic review of oncology clinical trials that were stopped for efficacy at the interim analysis, relatively large differences were noted between the unadjusted and adjusted HRs when the number of events at the interim analysis was small or when the unadjusted HR was close to the boundaries. These findings suggest presenting the 2 bias-adjusted HRs along with the unadjusted HR in the data monitoring committee meeting.
Trp53 and Rb1 regulate autophagy and ligand-dependent Hedgehog signaling
Authors: Catherine R. Cochrane, Vijesh Vaghjiani, Anette Szczepny, W. Samantha N. Jayasekara, Alvaro Gonzalez-Rajal, Kazu Kikuchi, Geoffrey W. McCaughan, Andrew Burgess, Daniel J. Gough, D. Neil Watkins, Jason E. Cain
Journal: Journal of Clinical Investigation (2020)

Ligand-dependent activation of Hedgehog (Hh) signaling in cancer occurs without mutations in canonical pathway genes. Consequently, the genetic basis of Hh pathway activation in adult solid tumors, such as small-cell lung cancer (SCLC), is unknown. Here we show that combined inactivation of Trp53 and Rb1, a defining genetic feature of SCLC, leads to hypersensitivity to Hh ligand in vitro, and during neural tube development in vivo. This response is associated with the aberrant formation of primary cilia, an organelle essential for canonical Hh signaling through smoothened, a transmembrane protein targeted by small-molecule Hh inhibitors. We further show that loss of both Trp53 and Rb1 disables transcription of genes in the autophagic machinery necessary for the degradation of primary cilia. In turn, we also demonstrate a requirement for Kif3a, a gene essential for the formation of primary cilia, in a mouse model of SCLC induced by conditional deletion of both Trp53 and Rb1 in the adult airway. Our results provide a mechanistic framework for therapeutic targeting of ligand-dependent Hh signaling in human cancers with somatic mutations in both TP53 and RB1.
Plant Extracts May Relieve Hangover Symptoms, Trial Suggests
Authors: Anita Slomski
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prehabilitation vs Postoperative Rehabilitation for Frail Patients
Authors: Deborah S. Keller, Ben Carter, Susan J. Moug
Journal: JAMA Surgery (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
The efficacy and safety of influenza vaccination in older people: An umbrella review of evidence from meta-analyses of both observational and randomized controlled studies
Authors: Jacopo Demurtas, Stefano Celotto, Charlotte Beaudart, Dolores Sanchez-Rodriguez, Cafer Balci, Pınar Soysal, Marco Solmi, Daniele Celotto, Elena Righi, Lee Smith, Pier Luigi Lopalco, Vania Noventa, Jean Pierre Michel, Gabriel Torbahn, Francesco Di Gennaro, Damiano Pizzol, Nicola Veronese, Stefania Maggi
Journal: Ageing Research Reviews (2020)